Sort
15,842 grants matching “pancreatic cancer”
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival
$0Ann Richmond · Veterans Health Administration · I01 · FY2021 · VA
Impact of Inflammatory Pathway in Tumor Stroma on Pancreatic Cancer Growth
$0Vikas Dudeja · Birmingham Va Medical Center · I01 · FY2020 · VA
BLR&D Research Career Scientist Award Application
$0Hidekazu Tsukamoto · Va Greater Los Angeles Healthcare System · IK6 · FY2021 · VA
The role of PI3K in pancreatic cancer genetics and progression
$0Richard Z Lin · Northport Va Medical Center · I01 · FY2021 · VA
The Role of Cyr61 in Patho-Biology and Therapeutics of Pancreatic Cancer
$0Snigdha Banerjee · Kansas City Va Medical Center · I01 · FY2013 · VA
Role of Ron kinase in pancreatic cancer
$0James Freeman · South Texas Veterans Health Care System · I01 · FY2013 · VA
Novel Functions for Ras family GTPases
$0John P O'Bryan · Ralph H Johnson Va Medical Center · I01 · FY2023 · VA
Role of CD44 in adaptive plasticity of pancreatic cancer
$0James Freeman · South Texas Veterans Health Care System · I01 · FY2016 · VA
Role of serine protease KLK7 in pancreatic cancer
$0Randy S Haun · Central Arkansas Veterans Hlthcare Sys · I01 · FY2013 · VA
PHASE I TRIAL OF COMBINED THERAPY-L778123 &RADIOTHERAPY
$0Northwestern University · M01 · FY2000 · RR
Novel Reg4-CD44 Signaling Pathway in Colon Cancer
$0Brian Keith Dieckgraefe · St. Louis Va Medical Center · I01 · FY2016 · VA
Tumor tissue crosstalk in the macroenvironment of pancreatic cancer cachexia
$0Teresa A Zimmers · Portland Va Medical Center · I01 · FY2024 · VA
RFS 2000 ( 9 NITROCAMPTOTHECIN) IN PANCREAS CANCER
$0New York University School Of Medicine · M01 · FY2000 · RR
Novel Pathogenic Roles and Mechanisms of Fibrinogen in Pancreatic Cancer
$0Qizhi C. Yao · Michael E Debakey Va Medical Center · I01 · FY2025 · VA
Targeting GCNT3 for Pancreatic Cancer
$0Chinthalapally V. Rao · Oklahoma City Va Medical Center · I01 · FY2025 · VA
A Biomarker Risk Prediction Model for Prostate Cancer
$0Tamaro Syton Hudson · U.S. Dept/Vets Affairs Medical Center · IK2 · FY2015 · VA
GEMCITABINE, CISPLATIN ,AMIFOSTINE IN OVARIAN CANCER
$0New York University School Of Medicine · M01 · FY2000 · RR
Studies of Rare Cancers
$0Cancer Epidemiology And Genetics · Z01 · FY2004 · CP
Studies of Rare Cancers
$0Cancer Epidemiology And Genetics · Z01 · FY2003 · CP
Recombinant Toxins for Treatment of Hematologic Neoplasm
$0Basic Sciences · Z01 · FY2002 · BC
Immunotoxin Therapy of Solid and Hematopoietic Tumors: P
$0Basic Sciences · Z01 · FY2002 · BC
Targeted therapy of mesothelin expressing cancers using
$0Basic Sciences · Z01 · FY2005 · BC
Family Studies
$0Cancer Epidemiology And Genetics · Z01 · FY2005 · CP
Clinical Trials with Immunotoxins
$0Basic Sciences · Z01 · FY2005 · BC
ERK-Signaling in Microenvironment of Pancreatic cancer: Development of NovelTherapeutic Hypoxia-Responsive Nano-encapsulated ERK inhibitor
$0Sushanta K Banerjee · Kansas City Va Medical Center · I01 · FY2025 · VA